1 / 36

Clinical Trial Authorisation in Germany for First-in-Man Trials with NCEs

Clinical Trial Authorisation in Germany for First-in-Man Trials with NCEs. Thomas Sudhop, MD Presented by Christian Steffen, MD Federal Institute for Drugs and Medical Devices (BfArM) Germany. The TeGenero Incident. Trial Design.

thy
Download Presentation

Clinical Trial Authorisation in Germany for First-in-Man Trials with NCEs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Trial Authorisation in Germany for First-in-Man Trials with NCEs Thomas Sudhop, MD Presented by Christian Steffen, MD Federal Institute for Drugs and Medical Devices (BfArM) Germany

  2. The TeGenero Incident

  3. Trial Design • Mono-centre, double-blind, randomised first-in-man trail on TGN1412 • TGN1412: CD-28 “super-agonist” antibody • Trial population: 32 healthy volunteers in 4 cohorts • 0.1 mg/kg, 0.5 mg/kg, 2 mg/kg, 5 mg/kg • First cohort: 8 subjects • 6 TGN1412 0.1 mg/kg, 2 Placebo • Acute cytokine release syndrome in all six subjects treated with TGN1412 • Life-threatening • Requiring ICU treatment

  4. Clinical Course Suntharalingam et al. NEJM 2006

  5. Suntharalingam et al. NEJM 2006

  6. NATURE BIOTECHNOLOGY VOLUME 24 NUMBER 5 MAY 2006 Schneider et al., NATURE BIOTECHNOLOGY VOLUME 24 NUMBER 5 MAY 2006

  7. Cytokine Release Suntharalingam et al. NEJM 2006

  8. Relevant Guidelines for Clinical Trials • Non-Clinical Safety Studies For The Conduct Of Human Clinical Trials For Pharmaceuticals (ICH M3; CPMP/ICH/286/95) • Preclinical safety evaluation of biotechnology-derived pharmaceuticals (ICH S6; CPMP/ICH/302/95) • The Non-clinical Evaluation of the Potential for delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals (ICH S7B; CPMP/ICH/423/02) • Safety pharmacology studies for human pharmaceuticals (ICH S7A; CPMP/ICH/539/00) • Guideline for Good Clinical Practice (ICH E6; CPMP/ICH/135/95) • General Considerations for Clinical Trials (ICH E8; CPMP/ICH/291/95) • Guideline on Virus Safety Evaluation of Biotechnological Investigational Medicinal Products – Draft (EMEA/CHMP/BWP/398498/2005-corr) • Guideline on the Requirements to the Chemical and Pharmaceutical Quality Documentation concerning Investigational Medicinal Products in Clinical Trials (CHMP/QWP/185401/2004) • EUDRALEX- Vol. 10 – Clinical trials • … more

  9. Regulatory Actions • March 23rd, 2006 TGN1412 incident at Northwick Park Hospital, London • April 2006 MHRA published interim actions on mABs • April 2006 Publication of the TGN1412 IMP dossier • May 2006 UK Expert Scientific Group on Phase One Clinical Trials (ESGPOCT) founded • May 2006 German PEI published possible criteria for high-risk mABs • July 2006 ESGPOCT published interim report • July 2006 French AFSSAPS published concept paper • September 2006 BfArM drafted concept paper (internal use only) • November 2006 Final Report of the ESGPOCT • January 2007 EMEA announces CHMP-SWP Guideline • March 2007 CHMP-SWP Guideline published for public consultation

  10. Report of the Working Party on Statistical Issues in First-in-Man studies Royal Statistical Society March 2007

  11. How to improve current Practice? • First in man trial bear multiple risks due to limited data on the IMP and the interaction of IMP and human body • Unfortunately this part of clinical development had virtually no commonly accepted guidelines • A Guideline on Requirements for First-in-Man Clinical Trials for potential high-risk medicinal products has been published now for public consultation by the SWP of the EMEA • Both German competent authorities have been involved (PEI, BfArM)

  12. Definition of potential high-risk IMP Quality aspects Non-clinical requirements Clinical requirements First-in-man guideline

  13. Risk Assessment by Risk Classes • High Risk Trials • Difficult to express general guidance • Require a very special assessment • Non-High Risk Trials • Intermediate risk trials • Low risk trials

  14. Monoclonal Antibodies (mAb)* The mAb employs a new mechanism of action The mAb addresses a target that lacks appropriate animal models The mAb comprise a new type of engineered structural format NCEs The NCE is new in class and employs a new mechanism of action. It is reasonable to consider that the mechanism of action might fundamentally affect clinical relevant important vital systems such as the respiratory, immune, cardiovascular, gastrointestinal tract, CNS, and other vital body systems The NCE is new in class and addresses a target or pathway that lacks relevant nonclinical models. Definition of High-Risk IMPs *Schneider CK, Kalinke U, and Löwer J. TGN1412 - a regulator’s perspective. Nature Biotechnology 2006;24:493-6

  15. High-Risk IMPs • An IMP has to be considered as high-risk IMP when there are concerns that serious ADRs may occur in first-in-man trials • Case-by-case decision based on knowledge or uncertainties • Mode of action • Nature of target • Relevance of non-clinical models

  16. Intermediate- / Low-Risk Trials Intermediate-Risk Trials • neither classified as high risk trial • nor as low risk trial Low-Risk Trials • IMP is member of a well known and well characterised class of medicinal products or is second in class and the class has well described pharmacological properties and • prior clinical trials did not exert any unforeseeable risk then a clinical trial should be considered as a low risk trial.

  17. High-Risk Trials: Non-clinical DataPharmacodynamics • Primary and secondary pharmacodynamics • in in vitro animal and human systems and • in vivo in one or more chosen animal models • including • receptor binding • receptor occupancy • duration of effect • dose-response • Appropriate titration necessary to detect possible U- or bell-shaped dose response curves

  18. High-Risk Trials: Non-clinical DataPharmacokinetics • Standard ADME program for all species used for in-vivo studies • Absorption, Distribution, Metabolism and Elimination • Exposure data at pharmacological doses from the relevant animal models should be provided

  19. Trial Population • Health status • Healthy volunteers or patients? • Primary purpose is to assess tolerability and PK not therapeutic benefit • No parallel inclusion of the same subjects in other trials • Definition of “healthy” • Patients: Effect of concomitant treatment • Gender • Women in ‘first in man’ trials? • Age range • Ethnics

  20. Effect Log dose Starting Dose • Characteristics of an optimum and safe starting dose • It does not cause any clinical measurable effects • neither pharmacodynamic • nor toxic effects • dose prior MED / PAD (minimal effective dose, pharmacologically active dose) • The next higher dose causes first pharmacological effects (if detectable in healthy volunteers) without toxic effects • MED

  21. How to obtain a safe starting Dose • Classic approach: NOAEL / safety factor (>10) • Usually derived from doses rather than exposures • NOEL, PAD (Pharmacologically active dose) • Allometric Methods according FDA Guidance • Human equivalent dose (HED) according FDA recommendations is usually calculated on animal NOAELs • PAD adjustment might be necessary • NOAEL-HED Approach: Combining NOAELs with HED plus safety factor Guidance for industry and reviewers: Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers, July 2005, http://www.fda.gov/CDER/guidance/5541fnl.pdf

  22. MABEL Approach • Recommended for high-risk first-in-man trials • MABEL: “Minimal anticipated biological effect level” • Based on all relevant in-vitro and in-vivo PK and PD data such as • Receptor binding and receptor occupancy • Concentration/response data • Exposures at pharmacological doses in relevant species • MABEL should be calculated based on PK/PD modelling approach • Starting dose = MABEL dose / Safety factor • If NOAEL-HED dose is lower, use NOAEL-HED-derived dose

  23. Dose Regimen • First dose • Route of administration • Number of subjects per dose increment (cohort) • Number of subjects to be dosed at the same time • Time lag between dosing of the next subjects of • the same dose level (within cohort) • the next higher dose level (between cohorts) • Dose progression factor • When to stop (who and when)

  24. Dosing in High-Risk Trials • Initial sequential dose administration design within each cohort • Adequate period of observation between the administration of each subject depending on estimated PK and PD data • Before administration of the next cohort all results from all subjects of the subsequent cohort(s) must be reviewed • PK and PD data from the previous cohorts should be compared to known non-clinical PK, PD and safety information

  25. When to stop • Common approach • From MED (minimum effective dose) to MTD (maximum tolerated dose) • Nevertheless MTD not needed to be assessed in every IMP • How to assess the MTD? • From MID (Minimum intolerated dose) to MTD • MTD => last dose level below MID • Who is responsible for the stopping decision? • Role of the investigator (physician) • All stopping procedures and responsibilities should be clearly explained in the trial protocol

  26. Dose Escalation • Standard procedure • Arithmetic or geometric increase • Relevant factors • Steepness of the slope of dose/effect and dose/toxicity relations • Therapeutic range in non-clinical models • Predictability (raw estimate) of the effects of the next dose step • Potential pharmacodynamic effects (if any) • Potential toxic effects • …

  27. Cohort Size • With larger cohorts usually more precise data can be obtained, but larger cohorts put more subjects at risk and increase the costs of clinical development programmes • Common standard is an A + P design • with A = 6 to 10 subjects receiving the active product and • P = 2 to 4 subjects receiving placebo

  28. Number of subjects dosed simultaneously • High risk trials • not more than one subject • sequential administration design within each cohort • Intermediate risk trials • not more than two subjects per new dose level at first • Staggered administration designs • suitable for several cohort sizes (6+2, 8+3, 10+3 …)

  29. Staggered Administration Design (6+2) For the next dosing day all relevant clinical and safety data must be available and reviewed

  30. Time Lag between administered Doses • High risk trials • Individually calculated, risk based lag time • Intermediate risk trials • Time lag between the first two subjects of each new dose level should be based on appropriate nonclinical estimates • tmax-based approach • Adjustment might be necessary in case of observed events with late onset

  31. Trial Centres for First-in-man Trials • High-risk Trials: • Appropriate clinical facilities • Medical staff with appropriate level of training and expertise and an understanding of the IMP, its target and mechanism of action • Immediate access to facilities for the treatment of medical emergencies (such as cardiac emergencies, anaphylaxis, cytokine release syndrome, convulsions, hypotension), • ready availability of Intensive Care Unit facilities.

  32. REPUBLIQUE FRANCAISE • Furthermore, without prejudging the terms and conditions governing the approval of research centres, which will be defined by ”arrêté”, it should be pointed out that each research centre should have set up standard operating procedures enabling the centre to ensure, the safety of volunteers, depending on the foreseeable risks associated with each drug and/or each protocol. Hence, the foreseeable risks associated with each clinical trial must be evaluated and, depending on this risk: • the roles of the pharmacologist and the resuscitator must be specified, and the resuscitator and the appropriate medical service must be informed beforehand. • the appropriate monitoring of subjects by medical and paramedical staff must be organised (modalities, qualifications of personnel, round-the-clock presence or not, care modalities, emergency procedures, etc.).

  33. Conclusion • Protocol design- no concomitant exposure to other IMPs • High risk trials - sequential administration design- non-sequential design has to be fully justified • Trial site - conducted by medical staff with training and expertise- immediate treatment of medical emergencies- ready availability of Intensive Care Unit- preferably single protocol and single site

More Related